Clinicopathological characteristics and eligibility for adjuvant olaparib of germline BRCA1/2 mutation carriers with HER2-negative early breast cancer.

Journal

NPJ breast cancer
ISSN: 2374-4677
Titre abrégé: NPJ Breast Cancer
Pays: United States
ID NLM: 101674891

Informations de publication

Date de publication:
16 Apr 2024
Historique:
received: 29 06 2023
accepted: 22 03 2024
medline: 17 4 2024
pubmed: 17 4 2024
entrez: 16 4 2024
Statut: epublish

Résumé

Following the survival benefit demonstrated in the OlympiA trial, one year of adjuvant olaparib is now recommended for all patients with germline BRCA1/2 pathogenic/likely pathogenic variants (PV) and high-risk, HER2-negative early breast cancer after chemotherapy. However, optimal identification of high-risk patients who may derive benefit from this genomically-directed therapy is debated. In this study, we sought to characterize the real-world proportion of gBRCA1/2 PV carriers eligible for adjuvant olaparib according to the OlympiA criteria, and to compare clinicopathologic characteristics and outcomes between eligible and ineligible patients.

Identifiants

DOI: 10.1038/s41523-024-00632-8 PMID: 38627457
pubmed: 38627457
doi: 10.1038/s41523-024-00632-8
pii: 10.1038/s41523-024-00632-8
doi:

Types de publication

Journal Article

Langues

eng

Pagination

28

Informations de copyright

© 2024. The Author(s).

Références

Breast Cancer Association Consortium. et al. Breast cancer risk genes - association analysis in more than 113,000 women. N. Engl. J. Med. 384, 428–439 (2021).
doi: 10.1056/NEJMoa1913948
Hu, C. et al. A population-based study of genes previously implicated in breast cancer. N. Engl. J. Med. 384, 440–451 (2021).
doi: 10.1056/NEJMoa2005936 pubmed: 33471974 pmcid: 8127622
Geyer, C. E. Jr et al. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high risk, early breast cancer. Ann. Oncol. 33, 1250–1268, (2022).
doi: 10.1016/j.annonc.2022.09.159 pubmed: 36228963
Tutt, A. N. J. et al. Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. N. Engl. J. Med. 384, 2394–2405 (2021).
doi: 10.1056/NEJMoa2105215 pubmed: 34081848 pmcid: 9126186
Morganti, S. et al. Adjuvant olaparib for germline BRCA carriers with HER2-negative early breast cancer: Evidence and controversies. Oncologist 28, 565–574, (2023).
doi: 10.1093/oncolo/oyad123 pubmed: 37210568 pmcid: 10322138
Center for Drug Evaluation & Research. FDA approves olaparib for adjuvant treatment of high-risk early breast cancer. U.S. Food and Drug Administration https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-adjuvant-treatment-high-risk-early-breast-cancer (2022).
EMA. Lynparza. European Medicines Agency https://www.ema.europa.eu/en/medicines/human/summaries-opinion/lynparza-1 (2022).
Tolaney, S. M. et al. Updated Standardized Definitions for Efficacy End Points (STEEP) in adjuvant breast cancer clinical trials: STEEP version 2.0. J. Clin. Oncol. 39, 2720–2731 (2021).
doi: 10.1200/JCO.20.03613 pubmed: 34003702 pmcid: 10166345
Johnston, S. R. D. et al. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol. https://doi.org/10.1016/S1470-2045(22)00694-5 (2022).
doi: 10.1016/S1470-2045(22)00694-5 pubmed: 36493792

Auteurs

Stefania Morganti (S)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA.
Broad Institute of MIT and Harvard, Boston, MA, USA.

Qingchun Jin (Q)

Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA.
ORCID: 0000-0001-6388-5123

Julie Vincuilla (J)

Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.

Ryan Buehler (R)

Division of Cancer Genetics and Prevention, Dana-Farber Cancer Institute, Boston, MA, USA.

Sean Ryan (S)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.

Samantha Stokes (S)

Broad Institute of MIT and Harvard, Boston, MA, USA.

Tonia Parker (T)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.

Elizabeth A Mittendorf (EA)

Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA.
Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA.

Tari A King (TA)

Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA.
Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA.

Anna Weiss (A)

Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA.
Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA.
Division of Surgical Oncology, University of Rochester Medical Center, Rochester, NY, USA.

Ann H Partridge (AH)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA.
ORCID: 0000-0002-4722-4824

Brittany L Bychkovsky (BL)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA.
Division of Cancer Genetics and Prevention, Dana-Farber Cancer Institute, Boston, MA, USA.
ORCID: 0000-0001-7969-0603

Giuseppe Curigliano (G)

Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
European Institute of Oncology IRCCS, Milan, Italy.
ORCID: 0000-0003-1781-2518

Nabihah Tayob (N)

Harvard Medical School, Boston, MA, USA.
Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA.
ORCID: 0000-0001-6088-167X

Nancy U Lin (NU)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA.

Judy E Garber (JE)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA.
Division of Cancer Genetics and Prevention, Dana-Farber Cancer Institute, Boston, MA, USA.

Sara M Tolaney (SM)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA.
ORCID: 0000-0002-5940-8671

Filipa Lynce (F)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. filipa_lynce@dfci.harvard.edu.
Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA. filipa_lynce@dfci.harvard.edu.
Harvard Medical School, Boston, MA, USA. filipa_lynce@dfci.harvard.edu.
ORCID: 0000-0001-6615-7076

Classifications MeSH